Profile data is unavailable for this security.
About the company
Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
- Revenue in EUR (TTM)9.03m
- Net income in EUR-25.04m
- Incorporated2002
- Employees134.00
- LocationMedincell SA3 rue des Freres LumiereJACOU 34830FranceFRA
- Phone+33 467021367
- Websitehttps://www.medincell.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emergent Biosolutions Inc | 1.07bn | -197.65m | 511.37m | 1.60k | -- | 1.06 | -- | 0.48 | -4.10 | -4.10 | 21.19 | 9.40 | 0.6678 | 2.21 | 6.66 | 703,437.50 | -12.39 | -2.94 | -16.86 | -3.66 | 33.51 | 53.24 | -18.55 | -5.95 | 1.47 | -1.20 | 0.5658 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Beijing Luzhu Biotechnology Co Ltd | 0.00 | -36.63m | 512.28m | 148.00 | -- | 4.18 | -- | -- | -1.49 | -1.49 | 0.00 | 5.02 | 0.00 | -- | -- | 0.00 | -23.80 | -- | -25.44 | -- | -- | -- | -- | -- | 5.91 | -- | 0.0296 | -- | -- | -- | 65.62 | -- | -- | -- |
| JCR Pharmaceuticals Co Ltd | 214.68m | -2.66m | 514.08m | 934.00 | -- | 1.44 | 27.01 | 2.39 | -3.49 | -3.49 | 281.91 | 451.84 | 0.338 | 0.4791 | 2.15 | 37,747,320.00 | -0.3864 | 8.66 | -0.5681 | 13.46 | 71.44 | 74.51 | -1.14 | 18.24 | 0.9827 | -0.8184 | 0.3325 | 30.60 | 24.83 | 13.11 | 46.00 | 8.19 | 18.54 | 21.67 |
| Hunan Warrant Pharmaceutical Co Ltd | 189.48m | 27.70m | 517.35m | 1.16k | 18.68 | 2.10 | -- | 2.73 | 2.25 | 2.25 | 15.42 | 20.06 | 0.6426 | 1.49 | 9.74 | 1,244,707.00 | 8.34 | 11.21 | 9.79 | 14.05 | 61.32 | 69.00 | 12.98 | 13.96 | 3.18 | -- | 0.0566 | 8.05 | 10.84 | 18.50 | 15.60 | 19.02 | 24.49 | -- |
| Medincell SA | 9.03m | -25.04m | 523.39m | 134.00 | -- | -- | -- | 57.95 | -0.8754 | -0.8754 | 0.3178 | -1.40 | 0.2725 | -- | 5.99 | 67,402.98 | -75.54 | -61.75 | -- | -167.61 | 74.92 | 71.74 | -277.21 | -366.40 | -- | -5.23 | 3.25 | -- | -8.67 | 44.33 | 21.78 | -- | 9.57 | -- |
| Beijing Konruns Pharmaceutical Co Ltd | 110.87m | 15.04m | 525.50m | 447.00 | 34.29 | 1.25 | -- | 4.74 | 0.7311 | 0.7311 | 5.38 | 20.03 | 0.2178 | 1.95 | 2.90 | 1,893,258.00 | 3.81 | 5.43 | 4.48 | 6.24 | 87.83 | 89.93 | 17.52 | 20.76 | 3.36 | -- | 0.0582 | 21.53 | 6.15 | -2.08 | 48.24 | -10.63 | 43.05 | -9.71 |
| Ocumension Therapeutics | 40.60m | -42.23m | 526.18m | 477.00 | -- | 1.23 | -- | 12.96 | -0.5296 | -0.5296 | 0.509 | 4.29 | 0.103 | 2.40 | 2.48 | 751,613.10 | -10.71 | -38.78 | -11.55 | -41.47 | 58.29 | 62.30 | -104.01 | -975.82 | 5.00 | -- | 0.0055 | -- | 54.99 | -- | 5.68 | -- | 319.66 | -- |
| Shanghai Fudan Forward S&T Co Ltd | 83.71m | -2.00m | 530.15m | 1.36k | -- | 5.24 | -- | 6.33 | -0.0222 | -0.0222 | 0.9345 | 1.13 | 0.3799 | 0.6476 | 8.53 | 468,807.20 | -0.9863 | -0.8781 | -1.68 | -1.53 | 36.63 | 43.22 | -2.60 | -1.85 | 0.413 | -2.40 | 0.3319 | -- | -13.86 | -7.58 | 196.17 | -32.57 | -13.88 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Mirova SA (Investment Management)as of 27 Sep 2024 | 2.06m | 7.06% |
| Polar Capital LLPas of 30 Sep 2024 | 741.09k | 2.55% |
| Syquant Capital SASas of 31 Dec 2023 | 728.73k | 2.50% |
| Amundi Asset Management SA (Investment Management)as of 30 Aug 2024 | 563.39k | 1.94% |
| BFT Investment Managers SAas of 30 Aug 2024 | 332.14k | 1.14% |
| Saint Olive Gestion SNCas of 31 Aug 2024 | 275.03k | 0.95% |
| Financi�re Arbevel SAas of 30 Aug 2024 | 175.31k | 0.60% |
| Mandarine Gestion SAas of 28 Jun 2024 | 157.00k | 0.54% |
| SG 29 Haussmann SASUas of 07 Nov 2024 | 135.00k | 0.46% |
| Portzamparc Gestion SAas of 30 Aug 2024 | 115.00k | 0.40% |
